Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) In Coronary Stenosis Trial

Trial Profile

BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) In Coronary Stenosis Trial

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 May 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ridaforolimus (Primary) ; Zotarolimus
  • Indications Coronary artery restenosis; Ischaemic heart disorders
  • Focus Therapeutic Use
  • Acronyms BIONICS
  • Sponsors Medinol
  • Most Recent Events

    • 26 May 2020 Planned End Date changed from 1 Aug 2020 to 1 Nov 2021.
    • 14 Apr 2020 Results of subgroup analysis published in the American Journal of Cardiology
    • 25 Sep 2018 Results assessing 2-year clinical outcomes of the pooled BIONICS and NIREUS Trials presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top